This is the author's final, peer-reviewed manuscript as accepted for publication. The publisher-formatted version may be available through the publisher's web site or your institution's library.

Stem cell-based photodynamic therapy

Tej B. Shrestha, Gwi M. Seo, Matthew T. Basel, Mausam Kalita, Hongwang Wang, David Villanueva, Marla Pyle, Deryl L. Troyer, and Stefan H. Bossmann

How to cite this manuscript

If you make reference to this version of the manuscript, use the following information:

Shrestha, T. B., Seo, G. M., Basel, M. T., Kalita, M., Wang, H., Villanueva, D., . . . Bossmann, S. H. (2012). Stem cell-based photodynamic therapy. Retrieved from <http://krex.ksu.edu>

Published Version Information

Citation: Shrestha, T. B., Seo, G. M., Basel, M. T., Kalita, M., Wang, H., Villanueva, D., . . . Bossmann, S. H. (2012). Stem cell-based photodynamic therapy. *Photochemical & Photobiological Sciences*, 11(7), 1251-1258.

Copyright: © The Royal Society of Chemistry and Owner Societies 2012

Digital Object Identifier (DOI): doi:10.1039/c2pp05417e

Publisher's Link: <http://pubs.rsc.org/en/Content/ArticleLanding/2012/PP/c2pp05417e>

This item was retrieved from the K-State Research Exchange (K-REx), the institutional repository of Kansas State University. K-REx is available at <http://krex.ksu.edu>

Stem Cell-Based Photodynamic Therapy: 1. *in Vitro* Studies

Tej B. Shrestha,^{*a,b} Gwi M. Seo^a, Matthew T. Basel^{a,b}, Mausam Kalita^{a,b}, Hongwang Wang^b, David Villanueva^b, Marla Pyle^a, Deryl L. Troyer^{*a} and Stefan H. Bossmann^{*b}

⁵ Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

We have transfected murine neural stem cells (NSCs) with a plasmid expressing *Gaussia* luciferase (gLuc). The enzyme is secreted from the cells. We have used the gLuc-containing supernatant from cultured NSCs to perform *in vitro* photodynamic therapy of murine melanoma cells (B16F10). The treatment system was comprised of 5-aminolevulinic acid as a prodrug for the synthesis of the photosensitizer protoporphyrin IX, *Gaussia* luciferase, and its substrate, coelenterazine. A significant reduction in the number of live melanoma cells was observed 36h after coelenterazine-mediated PDT.

Introduction

In the search for new cancer treatment methods able to overcome the multi-drug resistance found in many cancer types, it will be advantageous to try new approaches. Classic chemotherapy focuses on killing cells that are dividing rapidly. Unfortunately, many other cells in the body also divide rapidly, causing many of well-known chemotherapy side effects (e.g. fatigue from low red blood cell count, susceptibility to infection from wiping out the white blood cells, and weight loss because of the lack of functioning intestinal cells).^{1,2} Classic chemotherapy often fails because these side effects prevent administering doses of these anticancer drugs adequate to kill the tumour cells. Photodynamic therapy (PDT) has been successful in treating non-hypoxic tumours, which were conveniently located to permit high doses of incident light.³ To date, the U.S. Food and Drug Administration (FDA) has approved the photo-sensitizing agent porfimer sodium (Photofrin®), for use in PDT for the treatment of esophageal cancer⁴, non-small cell lung cancer⁴ and of precancerous lesions in patients with Barrett's esophagus (a condition that can lead to esophageal cancer). The main obstacle to a prevalent application of PDT is not the enrichment of photodynamic drugs within tumours, but the availability of light sources that provide sufficiently high doses in the appropriate excitation windows for mono-photon and bi/multi-photon excitation. The light absorption coefficients of water and human aorta tissue possess a minimum region of tissue absorption at 800±50nm. This corresponds to maximal light penetration depths (δ)⁵ of 1cm at 800nm, 0.5cm at 600nm and 900nm, and 0.1cm at 400nm.^{5,6} Numerous strategies for enhanced irradiation of tumours that are located within the human or mammalian body are discussed in the literature.⁷ Among these approaches are the use of high-energy lasers instead of lamps⁷, laser diodes⁸, fiber-optical devices for the *in situ* irradiation of the interstitium⁹, the use of gold nanoshells and nanocages as high absorption and scattering materials¹⁰, and bi- and multi-photon excitation of

suitable chromophores.¹¹ Bi- and multiphoton absorption offers the advantage of spatially resolved irradiation and higher selectivity than mono-photon excitation, especially when femtosecond pulses are used.¹¹ However, the light intensities required for the simultaneous absorption of two or several photons are very hard to achieve when treating tumours within the human/mammalian body, because the two- and multi-photon absorption cross-sections are generally low.¹¹

Early detection of tumours and especially their metastases is crucial for cancer treatment. Traditionally, tumour detection is achieved by various methods, including magnetic resonance imaging and computerized tomography. The recent advances in life science and bioengineering permit the transfection, cellular expression, and real-time imaging of light-emitting proteins, such as *Renilla* luciferase (Ruc), bacterial luciferase (Lux), or fluorescent proteins, such as firefly luciferase (Luc), green fluorescent protein (GFP), or Ruc-GFP fusion protein.¹² All of these marker proteins, which generate bioluminescence by chemical processes¹², have been successfully employed for tumour detection. Since no excitation light is required, there is no background fluorescence and, consequently, a much improved signal to noise ratio. It has also been demonstrated that certain bacteria (e.g. *Clostridium* and *Bifidobacterium*¹³), viruses¹⁴, and neural stem cells¹⁵, when administered systemically, are able to gain entry to and replicate selectively in tumours. In addition many tissue/tumour specific promoters have been cloned, allowing transgene expression specifically in tumour tissues.¹⁶ Here we describe the transfection of murine neural stem cells with *Gaussia* luciferase. *Gaussia*, a calanoid copepod, about 6mm in size, is a member of the planktonic community. *Gaussia* luciferase has a molecular weight of only 19.9 kDa, which makes it the smallest luciferase using coelenterazine as substrate.¹⁷⁻¹⁹ It is noteworthy that *Gaussia* luciferase is approx. 750-fold brighter than native *Renilla* luciferase (when consuming the same amount of substrate).²⁰ In the work reported here, neural stem cells secreting *Gaussia* luciferase were cultured. Murine B16F10

melanoma cells were then treated with the resulting culture medium containing *Gaussia* luciferase and its substrate coelenterazine (COEL).¹⁶⁻¹⁹ ALA (5-aminolevulinic acid) was given to the B16F10 cells prior to PDT. ALA is the prodrug for the biosynthesis of the photosensitizer protoporphyrin IX (PpIX) in the cancer cells' mitochondria.^{21,22} The effects all three components (ALA, COEL, and bioluminescence alone) on the cancer cells as a function of time is discussed in this report. The structures of ALA, protoporphyrin IX, and coelenterazine are shown in Scheme 1.

Scheme 1: Structures of aminolevulinic acid (1), protoporphyrin IX (2) and coelenterazine (3).

Results and Discussion

The first attempt to use bioluminescence from NIH 3T3 murine fibroblasts, which were transfected with firefly luciferase, was reported in 2003 by A. J. MacRobert and coworkers.²³ The cells were loaded with D-luciferin and the photosensitizer rose bengal featuring a quantum yield of singlet-oxygen sensitization of $\Phi_A=0.75\pm0.05$ in aqueous media.²³ The emission spectrum of luciferase/ATP oxyluciferin and the absorption spectrum of rose bengal match very nicely. In such a case, the excitation of rose bengal can be achieved by either reabsorption of the bioluminescence or through Förster energy transfer.²⁴ The bioluminescence from firefly luciferase requires D-luciferin and ATP. In the presence of luciferase, D-luciferin and rose bengal, the cell survival rate dropped from 100% to 11% after 24h.²³ Although this initial study demonstrated the potential of *in situ* PDT, it had the following drawbacks with respect to possible *in vivo* applications: 1) the cell that is to be treated has to be transfected with the gene of a bioluminescent enzyme first; and 2) rose bengal is a very good sensitizer for technical applications, such as vitamin D synthesis²⁵, however, it is toxic to cells.²⁶ A suitable therapeutic system should comprise a non-toxic sensitizer and cells that are able to migrate to solid tumours and secrete the bioluminescent enzyme. The singlet oxygen sensitization by the sensitizer should be sufficient to permit the efficient generation of singlet oxygen, even in the usually hypoxic tumour environment.

A Neural Stem Cell-Based *in Vitro* System for Photodynamic Therapy of Melanoma

Mouse neural stem cells (C17.2 immortalized cells) were transfected with a plasmid containing the gene for *Gaussia*

luciferase (Nanolight).²⁷ Mouse neural stem cells (NSC) were used because they are known to "home" to numerous solid tumours.¹⁵ The pGLuc-basic-1 vector contains the "humanized" coding sequence for secreted *Gaussia* luciferase (gLuc), for use in mammalian cells. The medium containing gLuc secreted from the C17.2 cells was harvested at 24 hours and used to treat B16F10 mouse melanoma cells that had been independently cultured and treated with the supernatant from the mouse neural stem cells. Figure 1 shows the cell cultures of the mouse neural stem cells (A) and B16F10 mouse melanoma cells (B).

Figure 1: A: C17.2 neural stem cells (mouse NSC), 20x magnification; B: B16F10 melanoma cells, 20x magnification.

The emission spectrum of the bioluminescence emitted from the supernatant in the presence of coelenterazine is shown in Figure 2. The bioluminescence occurs during the oxidation of coelenterazine to coelenteramide by gLuc, as shown in Scheme 2.

Figure 2: Emission from gLuc: 2mL of supernatant from the medium in which gLuc transfected neural stem cells (NSC) have been grown for 24h, to which was added 8 μ L of coelenterazine (1mg/mL) in β -cyclodextrin, ratio coelenterazine:cyclodextrin = 1:50).

Figure 3 shows the kinetics of light emission from the supernatant of the C17.2 cells in the presence of coelenterazine.

Figure 3: Time-profile of the bioluminescence occurring from gLuc: 100 μ L of supernatant from the medium, in which gLuc transfected neural stem cells (NSC) have been grown for 24h, 8 μ L of coelenterazine (1mg/mL) or 8 μ L of coelenterazine in β -cyclodextrin, ratio coelenterazine:cyclodextrin = 1:50).

Secreted gLuc is very stable under the conditions reported here, as indicated by first-order kinetics after the addition of coelenterazine. It is noteworthy that secreted gLuc retained its catalytic activity for up to 1 year at 195K and for up to one month at 277K. The observed bisexponential first order kinetics can be explained by the heterogeneity of the supernatant from culturing gLuc secreting NSC's. Although coelenterazine (COEL) is more hydrophobic ($\log P = 3.406^{28}$) than its β -cyclodextrin (COEL_CD) adduct ($\log P = -1.2^{28}$), the addition of free COEL resulted in a higher photon flux within 90min. after mixing (total measured photon flux: $1.37 \pm 0.05 \times 10^{12}$ photons (COEL) vs. $9.90 \pm 0.05 \times 10^{11}$ photons (COEL_CD). The crossover between the bioluminescence decay of COEL and the COEL-CD was observed after 2535s at low photon flux (1.083×10^8 photons s^{-1}). In spite of its higher hydrophobicity, free COEL is soluble in our culture medium at a concentration of 1.75×10^{-8} mol. We attribute its higher efficiency of bioluminescence to the fact that only free COEL reacts with gLuc. Therefore, the catalytic activity of gLuc depends on the dissociation of the supramolecular COEL-CD complex. The half-lives of the gLuc catalyzed bioluminescence of COEL were determined to be $263s \pm 10s$ ($k_1 = 0.002627 s^{-1}$) and $1547s \pm 73 s$ ($k_2 = 0.000448 s^{-1}$) (see SI). For the COEL-CD complex, we have obtained $175s \pm 8s$ ($k_1 = 0.003961 s^{-1}$) and $2278s \pm 88 s$ ($k_2 = 0.000304 s^{-1}$) under identical conditions.

The maximal photon total flux, as measured by an IVIS® Lumina Live Imaging device (Caliper Life Sciences) and calculated by integrating Figure 3 was $1.368 \pm 0.005 \times 10^{12}$ photons. However, the detection geometry of the IVIS system does not permit the straightforward calculation of bioluminescence conversion efficiencies. 1.05×10^{16} molecules of coelenterazine were added to the well. Only 0.026% of coelenterazine molecules emitted photons that reached the IVIS detection system. Considering the IVIS geometry and depending on assumptions for scattering and self-absorption, the coelenterazine to bioluminescence conversion efficiency within 90 min. is approximately 10-50 times higher.

Gaussia-Luciferase Based Photodynamic Therapy of Mouse Melanoma Cells

We have used the supernatant from gLuc-expressing neural stem cells (NSCs) to study the photodynamic effect of protoporphyrin IX on B16F10 (mouse melanoma) cells. gLuc expressing NSCs (5×10^4 cells) were suspended in 1.0ml of their growth medium. The B16F10 cells were incubated at 310K with 5% CO₂ for 24 hours, after which ALA (2 mMol) was added. ALA is the substrate for the biosynthesis of protoporphyrin IX (PpIX) in the mitochondria of the cancer cells. Twenty four hours after changing the aqueous buffer to the supernatant from culturing the gLuc transfected NSCs, coelenterazine (8 μ g/ μ l) was added as water-soluble β -cyclodextrin-complex. After addition of coelenterazine, viable cancer cell numbers were analyzed over a 36 hours period using an MTT assay.²⁹ All experiments were done in triplicate and repeated at least three times. The results are shown in Figure 4 (12h after treatment), Figure 5 (24h after treatment) and Figure 6 (36h after treatment). To distinguish the

effect of this photodynamic therapy system on B16F10 cell viability and cytotoxic/growth augmenting effects that occur in the dark, the following control groups were used: 1) B16F10 cells (no treatment); 2) B16F10 cells in the presence of ALA (aminolevulinic acid); 3) B16F10 cells in the presence of coelenterazine; 4) B16F10 cells in the presence of coelenterazine

and gLuc (=bioluminescence). The treatment group consisted of B16F10 cells that were cultured in the presence of gLuc, ALA (2mmol L⁻¹) and coelenterazine (8 μ g/100 μ L⁻¹).

Figure 4: Effect on B16F10 melanoma cell viability of control cells (no treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, coelenterazine and NSC/gLuc (=bioluminescence), or full treatment (NSC/gLuc, ALA (2mmol L⁻¹), coelenterazine (8 μ g/100 μ L medium)), 12h after treatment.

Figure 4 indicates that ALA may be able to boost the cancer growth, when given alone. ALA is a precursor of porphyrin, heme, and bile pigments, and it is metabolized into protoporphyrin IX (PpIX) in the course of heme synthesis.³⁰ The autofluorescence of PpIX and heme is known to be a predictor of cancer development, because the biosynthesis of porphyrins is upregulated in many cancers.³¹⁻³³ It is apparent that enhanced biosynthesis of porphyrins in B16F10 melanoma cells due to the presence of the precursor ALA increases the melanoma cell growth. Porphyrins are essential molecules within cells and have multiple roles in essential cellular processes such as the mitochondrial electron transport chain, free-radical detoxification, and metabolic activity. Therefore, upregulating porphyrin biosynthesis is beneficial for the cancer cell.³⁴

Coelenteramide, which is formed from coelenterazine through enzymatic and non-enzymatic oxidation¹⁷⁻¹⁹ (see Scheme 2), shows discernible cell toxicity. The addition of gLuc apparently does not significantly increase this toxicity. This finding clearly demonstrated that the blue light emitted by the COEL/gLuc system does not harm the B16F10 cells, although the black melanomas are able to absorb the light. Apparently, the photon flux of the bioluminescence is not high enough to cause detectable harm. A detailed ANOVA analysis of these data, which is provided in the SI section, clearly indicates that the COEL and COEL/gLuc groups cannot be distinguished from the treatment group 12h after PDT.

Scheme 2: The oxidation of coelenterazine (3) to coelenteramide (4) is catalyzed by gLuc. In the absence of gLuc, coelenterazine is slowly decomposed (within 48h) in aerated aqueous buffer in the presence of three Ca^{2+} ions.¹⁷⁻¹⁹

Figure 5: Effect on B16F10 melanoma cell viability of control cells (no treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, coelenterazine and NSC/gLuc (=bioluminescence), or full treatment (NSC/gLuc, ALA (2 mmol L^{-1}), coelenterazine ($8\mu\text{g}/100\mu\text{L}$ medium)), 24h after treatment.

Figure 5 shows that 24h after treatment, all groups remain essentially unchanged, except the treatment group, which is at that time statistically significantly reduced. This finding can be regarded as proof that stem cell based photodynamic therapy is really working *in vitro*. The delayed response of B16F10 melanoma cells to PDT is an indication of apoptosis as the mode of cell death.³⁵ It must be noted that an ANOVA analysis of the data summarized in Figure 5 indicates that the COEL and COEL/gLuc control groups cannot be distinguished from the treatment group 24h after PDT.

Figure 6: Effect on B16F10 melanoma cell viability of control cells (no treatment), ALA (aminolevulinic acid) alone, coelenterazine alone, coelenterazine and NSC/gLuc (=bioluminescence), or full treatment (NSC/gLuc, ALA (2 mmol L^{-1}), coelenterazine ($8\mu\text{g}/100\mu\text{L}$ medium)), 36h after treatment.

Figure 6 shows that the irradiated and non-irradiated mouse melanoma cells have recovered from the coelenteramide toxicity after 36h. ALA is still beneficial to melanoma growth *in vitro*.

However, there is virtually no recovery of the treated group of cells. This finding is again in agreement with the hypothesis of apoptosis as the mode of cell death. It also shows that all components of the treatment (ALA, COEL and gLuc) are required to result in a lasting treatment effect! As ANOVA indicates, 36h after PDT, the treatment group is significantly different from all other groups ($p < 0.001$).

Experimental

The synthesis of aminolevulinic acid (ALA) has been performed according to a published procedure.³⁶ This team has developed a novel synthesis for coelenterazine (COEL).³⁷ Coelenterazine ($1\mu\text{g/mL}$) was dissolved in acidified MeOH (5 mmol HCl) under Ar and β -cyclodextrin (molar ratio 50:1) was added. After the mixture had completely dissolved, the solvent was removed in high vacuum. The white solid was then dissolved in PBS buffer, resulting in a coelenterazine concentration of $1\mu\text{g/mL}$.

gLuc transfection of C17.2 mouse neural stem cells

The immortalized C17.2 mouse neural stem cells (NSC) have been transfected using the pCMV-Gluc-1 plasmid (Cat#202, humanized *Gaussia* luciferase with secretory signal) from NanoLight Technology, Pinetop, AZ 85935. Due to the secretory signal, GLuc is secreted into the cell medium of cultured mammalian cells upon expression. NSCs were plated in 24 well plates in phenol red free NSC medium (Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich St. Louis, MO), 5% horse serum (Invitrogen), 1% glutamax (Invitrogen), and 1% penicillin/streptomycin (Invitrogen)) at 40,000 cells per well and incubated at 37°C for 24 hours. After 24 hours, cells were at 70-80% confluence. Medium was replaced with fresh NSC medium without phenol red. For each well of 24 well plate, $1\mu\text{g}$ of pCMV-Gluc-1 plasmid was diluted in $49\mu\text{L}$ serum free medium and $2\mu\text{L}$ of TurboFectTM *in vitro* transfection reagent (Fermentas, Life Science) was added to the medium and mixed well by vortexing. After incubation of the plasmid mixture at 25°C for 20 minutes, $52\mu\text{L}$ of the mixture was added to each well and gently mixed by rocking the plate. Then, cells were further incubated for 24 hour to allow secretion of gLuc.

Bioluminescence from gLuc

$100\mu\text{L}$ of supernatant from the medium in which gLuc transfected neural stem cells (NSC) had been grown for 24h at 310K, was added to $8\mu\text{L}$ of coelenterazine ($1\mu\text{g/mL}$) in β -cyclodextrin, ratio coelenterazine:cyclodextrin = 1:50. The resulting mixture was then imaged using an IVIS Lumina II system at 300K. The bioluminescence spectrum has been recorded using an ISA SPEX Fluoromax-2.

Cultures of C17.2 and B16F10 cells (ATCC (Manassas, VA))

C17.2 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS Sigma-Aldrich), 5% horse serum (Invitrogen), 1% glutamax (Invitrogen), and 1% penicillin/streptomycin

(Invitrogen). B16F10 cells were cultured in DMEM(Invitrogen, Carlsbad, CA) with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1%penicillin/streptomycin (Invitrogen)with 10% FBS (Fetal Bovine Serum), 5% Horse serum, 1% Glutamax, 1% Penstrap. Cells were grown overnight as monolayers at a concentration of 20,000 cells/cm² in 25-cm² flasks in 5-mL medium at 310K and 5% CO₂. After attaining 70% confluence (after 24h) the growth medium was removed. Trypsin EDTA (1mL) was added to facilitate the detachment of the cells. After 1 min., 3mL medium was added to stop the Trypsin EDTA reaction. The cells were then replated (at a 1:2 dilution). The conditioned medium (1:5, medium from culturing gLuc C17.2 cells:fresh medium of B16F10 without phenol red) was used for replacing medium of the B16F10 cells. This system was then used for the in-vitro PDT experiments.

MTT Assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was dissolved in PBS at 5.0 mg/mL (MTT reagent). MTT solubilization buffer was prepared by dissolving 10% (w/v) sodium dodecylsulfate and 0.1 M HCl in bidest. water. To assay cell viability, MTT reagent solution 1:10 (v/v, reagent solution/cell medium) was added to the cells and incubated at 310K for 4 h. Then, MTT solubilization buffer (medium/buffer=1:1) was added, followed by overnight incubation at 310K. The absorbance at 550 nm and 690 nm (as background) were measured using a plate reader (Spectra MAX190, Molecular Devices). The difference in absorbance between the two wavelengths is indicative of the number of live cells.

Experimental Design

Statistical analyses of the measured cell viabilities have been performed using the program WinSTAT (A-Prompt Corporation, Lehigh Valley, PA).³⁸ The means of the experimental groups have been evaluated to confirm that they meet the normality assumption. To evaluate the significance of overall differences in cell viability between all *in vitro* groups, statistical analysis has been performed by analysis of variance (ANOVA). A p-value less than 0.01 has been considered as significant.

Conclusions

Addition of media conditioned by *Gaussia* luciferase- secreting neural stem cells generates blue light after the addition of coelenterazine that can significantly attenuate B16 melanoma cells pre-exposed to 5-aminolevulinic acid. The attenuation effect was observed at 24 hours after treatment and was most significant relative to controls at 36 hours after PDT.

Acknowledgements

DT thanks Dr. V. Ourednik (Iowa State University) for the precious gift of mouse neural stem cells (C17.2 immortalized cells, originally developed by Dr. Evan Snyder). This research is based upon work supported by the National Science Foundation under Award No. CBET 933701.

Notes and references

- ^a Kansas State University, Anatomy & Physiology, Manhattan, KS 66506, USA. Fax: 001 785 532 4557; Tel: 001 785 532 4509; E-mail: tbs3@vet.k-state.edu; troyer@vet.k-state.edu
^b Kansas State University, Chemistry, Manhattan, KS 66506, USA. Fax: 001 785 532 6817; Tel: 001 785 532 6666; E-mail: sbossman@k-state.edu
[†] Electronic Supplementary Information (ESI) available: [¹H-NMR of aminolevulinic acid, ANOVA analysis of the in-vitro PDT experiment and analysis of bioluminescence kinetics]. See DOI: 10.1039/b000000x/

References

- 1 S. Marchini, M. D'Incalci and M. Broggin, *Curr Med Chem Anticancer Agents*, 2004, **4**, 247-262.
- 2 <http://www.cancer.gov/cancertopics/pdq/prevention/skin/>
- 3 D. E. Dolmans, D. Fukumura and R. K. Jain, *Nat Rev Cancer*, 2003, **3**, 380-387.
- 4 U.S. Food and Drug Administration (December 2003). Approved claims for palliative line therapy. Retrieved December 29, 2003, from: <http://www.accessdata.fda.gov>
- 5 B. C. Wilson and S. L. Jacques, *IEEE J Quantum Elect*, 1990, **26**, 2186-2199.
- 6 P. Taroni, A. Pifferi, A. Torricelli, D. Comelli and R. Cubeddu, *Photoch Photobi Sci*, 2003, **2**, 124-129.
- 7 Haedersdal, M.; Togsverd-Bo, K.; Wulf, H. C. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris., *J EADV* 2008, **22**, 267-78.
- 8 M. H. Schmidt, D. M. Bajic, K. W. Reichert, T. S. Martin, G. A. Meyer and H. T. Whelan, *Neurosurgery*, 1996, **38**, 552-556.
- 9 H. van den Bergh, J. Mizeret, J.-F. Theumann, A. Woodtli, R. Bays, D. Robert, P. Thielen, J.-M. Philippoz and D. Braichotte, *Proceedings of SPIE-The International Society for Optical Engineering*, 1995, **2631**, 173-198.
- 10 M. P. Melancon, W. Lu, Z. Yang, R. Zhang, Z. Cheng, A. M. Elliot, J. Stafford, T. Olson, J. Z. Zhang and C. Li, *Mol Cancer Ther*, 2008, **7**, 1730-1739.
- 11 K. Ogawa and Y. Kobuke, *Anti-Cancer Agent Me*, 2008, **8**, 269-279.
- 12 Y. A. Yu, T. Timiryasova, Q. Zhang, R. Beltz and A. A. Szalay, *Anal Bioanal Chem*, 2003, **377**, 964-972.
- 13 M. Babincova, P. Sourivong and P. Babinec, *Med Hypotheses*, 2000, **54**, 180-181.
- 14 B. Denes, N. Fodor, A. Obenaus and I. Fodor, *Open Biotechnology Journal* 2008, **2**, 252-261.
- 15 R. S. Rachakatla, S. Balivada, G. M. Seo, C. B. Myers, H. W. Wang, T. N. Samarakoon, R. Dani, M. Pyle, F. O. Kroh, B. Walker, X. X. Leaym, O. B. Koper, V. Chikan, S. H. Bossmann, M. Tamura and D. L. Troyer, *Acs Nano*, 2010, **4**, 7093-7104.
- 16 C. Moonen, *In Vivo MR Techniques in Drug Discovery and Development*, 2006, 301-311.
- 17 B. A. Tannous, D. E. Kim, J. L. Fernandez, R. Weissleder and X. O. Breakefield, *Mol Ther*, 2005, **11**, 435-443.
- 18 U. Griesenbach, C. C. Vicente, M. J. Roberts, C. X. Meng, S. Soussi, S. Xenariou, P. Tennant, A. Baker, E. Baker, C. Gordon, C. Vrettou, D. McCormick, R. Coles, A. M. Green, A. E. Lawton, S. G. Summer-Jones, S. H. Cheng, R. K. Scheule, S. C. Hyde, D. R. Gill, D. D. Collie, G. McLachlan and E. W. F. W. Alton, *Biomaterials*, 2011, **32**, 2614-2624.
- 19 Y. Inoue, F. Sheng, S. Kiryu, M. Watanabe, H. Ratanakanit, K. Izawa, A. Tojo and K. Ohtomo, *Mol Imaging*, 2011, **10**, 377-385.
- 20 B. Ballou, C. Szent-Gyorgi and G. Finley, in 11th international symposium on bioluminescence and chemiluminescence., Asilomar, CA, 2000.
- 21 J. Regula, A. J. MacRobert, A. Gorchein, G. A. Buonaccorsi, S. M. Thorpe, G. M. Spencer, A. R. W. Hatfield and S. G. Bown, *Gut*, 1995, **36**, 67-75.

-
- 22 T. J. Beck, F. W. Kreth, W. Beyer, J. H. Mehrkens, A. Obermeier, H. Stepp, W. Stummer and R. Baumgartner, *Laser Surg Med*, 2007, **39**, 386-393.
- 23 T. Theodossiou, J. S. Hotherhall, E. A. Woods, K. Okkenhaug, J. Jacobson and A. J. MacRobert, *Cancer Res*, 2003, **63**, 1818-1821.
- 24 A. Roda, M. Guardigli, E. Michelini and M. Mirasoli, *Anal Bioanal Chem*, 2009, **393**, 109-123.
- 25 M. Morisaki, J. Rubio-Lightbourn and N. Ikekawa, *Chemical & Pharmaceutical Bulletin*, 1973, **21**, 457-458.
- 26 S. H. Mousavi, J. Tavakkol-Afshari, A. Brook and I. Jafari-Anarkooli, *Food Chem Toxicol*, 2009, **47**, 855-859.
- 27 <http://www.nanolight.com/nanoligh.htm>
- 28 A. Petruskas, E. A. Kolovanov, *Perspectives in Drug Discovery and Design*, 2000, **19**, 99-116.
- 29 A. H. Cory, T. C. Owen, J. A. Barltrop and J. G. Cory, *Cancer Commun*, 1991, **3**, 207-212.
- 30 M. Ishizuka, F. Abe, Y. Sano, K. Takahashi, K. Inoue, M. Nakajima, T. Kohda, N. Komatsu, S. Ogura and T. Tanaka, *Int Immunopharmacol*, 2011, **11**, 358-365.
- 31 M. H. Bellini, E. L. Coutinho, L. C. Courrol, F. R. D. Silva, N. D. Vieira and N. Schor, *J Fluoresc*, 2008, **18**, 1163-1168.
- 32 L. C. Courrol, F. R. D. Silva, E. L. Coutinho, M. F. Piccoli, R. D. Mansano, N. D. Vieira, N. Schor and M. H. Bellini, *J Fluoresc*, 2007, **17**, 289-292.
- 33 K. Onizawa, N. Okamura, H. Saginoya and H. Yoshida, *Oral Oncol*, 2003, **39**, 150-156.
- 34 P. Krishnamurthy and J. D. Schuetz, *Curr Pharm Biotechnol*, 2011, **12**, 647-655.
- 35 J. Saczko, J. Kulbacka, A. Chwilkowska, M. Drag-Zalesinska, T. Wysocka, M. Lugowski and T. Banas, *Folia Histochem Cyto*, 2005, **43**, 129-132.
- 36 M. S. Kang, D. M. Kim, J. S. Kim and J. H. Jeong, *Arch Pharm Res*, 2005, **28**, 1111-1113.
- 37 T. B. Shrestha, D. L. Troyer, S. H. Bossmann, *J Org Chem*, submitted.
- 38 A. Riva, A. S. Carpentier, B. Torresani and A. Henaut, *Comput Biol Chem*, 2005, **29**, 319-336.